CR-mediated IGF-1 reduction also suppresses inflammation, another key contributor to cancer progression, by reducing the activation of pro-inflammatory pathways like NF-κB, which are often stimulated by IGF-1 signaling [164]. This evidence concerns the gene NFKB1 and cancer.